(Q38211361)

31 August 2017

Circulating tumour cells-monitoring treatment response in prostate cancer (English)

1 reference

31 August 2017

1 reference

2

Lecia V Sequist

1 reference

31 August 2017

David T Miyamoto

1

1 reference

PubMed ID

24821215

31 August 2017

Richard J Lee

series ordinal

3

1 reference

PubMed ID

24821215

31 August 2017

language of work or name

English

0 references

publication date

13 May 2014

1 reference

Nature Reviews Clinical Oncology

31 August 2017

1 reference

31 August 2017

11

1 reference

31 August 2017

7

1 reference

31 August 2017

401-412

1 reference

31 August 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Validation and clinical utility of prostate cancer biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

21 January 2018

Cancer micrometastases

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating tumor cells: approaches to isolation and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating tumor cells: liquid biopsy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating tumor cells and DNA as liquid biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Emerging therapies to prevent skeletal morbidity in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Computer-aided quantitative bone scan assessment of prostate cancer treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Analysis of circulating tumor DNA to monitor metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Considerations in the development of circulating tumor cell technology for clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Role of the EpCAM (CD326) in prostate cancer metastasis and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Development of a method to isolate circulating tumor cells using mesenchymal-based capture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

The VerIFAST: an integrated method for cell isolation and extracellular/intracellular staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Isolation of rare circulating tumour cells in cancer patients by microchip technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

NanoVelcro Chip for CTC enumeration in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Isolation of rare cells from cell mixtures by dielectrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Portable filter-based microdevice for detection and characterization of circulating tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Filter characteristics influencing circulating tumor cell enrichment from whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Standardized quantification of circulating peripheral tumor cells from lung and breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.82

Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24821215

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24821215

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24821215

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2014.82

1 reference

31 August 2017

1 reference

PubMed ID

24821215